20 research outputs found
Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study
The aim of this study was to compare the irinotecan/cisplatin regimen with cisplatin as second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) pretreated with a taxane/gemcitabine regimen. Patients (n=147) with stage IV NSCLC pretreated with a taxane/gemcitabine regimen were randomly assigned to receive either irinotecan (110 mg m−2, day 1 and 100 mg m−2, day 8) and cisplatin (80 mg m−2, day 8) (IC; n=74) or CDDP (80 mg m−2, day 1) (C; n=73) every 3 weeks. Patients treated with IC and C had a median survival of 7.8 and 8.8 months, respectively (P=0.933). The 1-year survival rate was 34.3% for IC-treated patients and 31.7% for C-treated patients. Cox's regression analysis revealed that response to treatment (hazard ratio (HR)=2.787; 95% confidence interval (CI): 1.1578–4.922) and performance status (HR=1.865; 95% CI: 1.199–2.872) was independent prognostic factors for survival. Overall response rate was 22.5% (95% CI: 12.8–32.2%) for IC-treated patients and 7.0% (95% CI: 1.15–13.6%) for C-treated patients (P=0.012); tumour growth control (partial remission (PR)+stable disease (SD)) was observed in 26 (38%) IC and 25 (36%) C patients (P=0.878). There was no difference in terms of quality of life between the two chemotherapy arms. The incidence of febrile neutropenia, grade 3 and 4 neutropenia and grade 3 and 4 diarrhoea was significantly higher in the IC- than the C-treated patients. Other toxicities were mild. There were no treatment-related deaths in either arm. The IC regimen did not confer a survival benefit compared with C as second-line treatment of patients with advanced NSCLC pretreated with a taxane/gemcitabine regimen, despite its better efficacy in terms of response rate
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study
A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer
<p>Abstract</p> <p>Background</p> <p>To compare the activity and toxicity of docetaxel/carboplatin (DC) doublet vs single agent docetaxel (D) as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC).</p> <p>Methods</p> <p>Patients pre-treated with front-line platinum-free regimens, were randomized to receive either docetaxel/carboplatin (DC), (docetaxel 50 mg/m<sup>2</sup>; carboplatin AUC4; both drugs administered on days 1 and 15) or docetaxel single-agent (D), (docetaxel 50 mg/m<sup>2 </sup>on days 1 and 15).</p> <p>Results</p> <p>Response rate was similar between the two arms (DC vs D: 10.4% vs 7.7%; p = 0.764). After a median follow-up time of 28.0 months for DC arm and 34.5 months for D arm, progression free survival (PFS) was significantly higher in the DC arm (DC vs D:3.33 months vs 2.60 months; p-value = 0.012), while no significant difference was observed in terms of overall survival (OS) (DC vs D: 10.3 months vs 7.70 months; p-value = 0.550). Chemotherapy was well-tolerated and grade III/IV toxicities were relatively infrequent. No toxic deaths were observed.</p> <p>Conclusions</p> <p>This study has not achieved its primary objective of significant OS prolongation with docetaxel/carboplatin combination over single-agent docetaxel in patients who had not received front-line docetaxel; however, the docetaxel/carboplatin combination was associated with a significant clinical benefit in terms of PFS.</p
Schematisation of concepts. A teaching strategy for environmental education implementation in a water module third grade students in junior high school (gymnasium-15 years old)
This article reports how a teaching strategy schematisation of concepts could influence the learning capability of third grade junior high school students. The teaching was planned and implemented within the framework of environmental education. A water module, water and its relationship with nature and contemporary man, was chosen for the teaching session. The study involved the participation of 171 third grade junior high school students (15 years of age), attending public schools in Athens and Thessaloniki. The sample was divided into an experimental group (N =84) and a control group (N= 87). The results of the investigation showed that the teaching strategy schematisation of concepts had a positive influence on the capability of junior high school students to structure: (a) causal relations of one link; (b) successive linear causal relations of more than one link; and (c) complex causal relations. © 2000, Taylor & Francis Group, LLC
Kindergarten teachers' conceptions of environmental education
A written questionnaire was used to obtain information regarding Greek kindergarten teachers' personal views on the concept of Environmental Education (EE). The questionnaire was also designed to obtain the teachers' views relative to a series of theoretical and methodological issues concerning the application of EE. It was ascertained that the prevalent conception of the kindergarten teachers includes the following: (a) it is directed towards a knowledge-centered type of EE, (b) it is primarily centered on nature and its protection in terms of EE content, (c) it aims not only to shape citizens willing to adopt environmental measures recommended by the experts, but who will also actively participate in social actions for the protection of the environment, (d) it favors learning procedures in the environment with field study activities, (e) it must be compulsory in the kindergarten level. © Springer Science+Business Media, Inc. 2006
Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: Preliminary results of a phase III trial of the hellenic oncology research group
Background: This trial was designed to compare the efficacy and toxicity of sequential versus alternating administration of cisplatin/etoposide and topotecan in patients with previously untreated extensive-stage small-cell lung cancer (SCLC). Patients and methods: Two hundred eighty-four chemotherapy-naive patients were randomized between the sequential therapy arm (n = 142; 4 cycles of cisplatin 75 mg/m2 intravenously [I.V.] on day 1 with etoposide 100 mg/m2 per day I.V. on days 1-3 followed by 4 cycles of topotecan 1.5 mg/m2 per day I.V. on days 1-5) and the alternating arm (n = 142; same doses of cisplatin/etoposide on cycles 1, 3, 5, and 7 and topotecan on cycles 2, 4, 6, and 8). Treatment cycles for both regimens were administered every 3 weeks. Results: At this preliminary analysis, no statistically significant difference in the overall response rate, duration of response, time to disease progression, or median survival was observed between the 2 arms. A total of 756 cycles of the sequential therapy and 830 cycles of the alternating therapy were administered, with a median numbers of 6 and 7 cycles per patient, respectively. Topotecan was administered in 85 patients on the sequential arm and 132 patients on the alternating arm. Dose reductions for toxicity were similar in both arms. Grade 3/4 toxicities in the sequential and alternating arms, respectively, included neutropenia (51% and 52%; P = NS), anemia (12% and 11%; P = NS), febrile neutropenia (7% and 9%; P = NS), thrombocytopenia (19% and 20%; P = NS), and asthenia (8% and 2%; P = 0.02). There were 4 toxicity-related deaths in the sequential arm versus 3 in the alternating arm. Conclusion: Our preliminary conclusion is that the sequential and alternating regimens resulted in comparable activity and tolerability in previously untreated patients with extensive-stage SCLC
Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial
Purpose To compare the overall survival (OS) of patients with advanced
non-small-cell lung cancer (NSCLC) treated with docetaxel plus cisplatin
(DC) or docetaxel (D) alone.
Patients and Methods Chemotherapy-naive patients with
advanced/metastatic NSCLC were randomly assigned to receive either DC (n
= 167; docetaxel 100 mg/m(2) on day 1, cisplatin 80 mg/m(2) on day 2,
and recombinant human granulocyte colony-stimulating factor (rhG-CSF)
150 mug/m(2)/d on days 3 to 9) or D (n = 152; 100 mg/m(2) on day 1
without rhG-CSF) every 3 weeks.
Results The overall response rates were 36.5% for DC (three complete
responses and 58 partial responses) and 21.7% for D (one complete
response and 32 partial responses; P = .004). The median OS was 10.5
months (range, 0.5 to 41 months) and 8.0 months (range, 0.5 to 41
months) for DC and D, respectively (P = .200). The 1- and 2-year
survival rates were 44% and 19% for DC and 43% and 15% for D,
respectively. Median times to tumor progression were 4.0 and 2.5 months
for DC and D, respectively (P = .580). Grade 2/3 anemia was
significantly higher with DC than with D (33% v 16%; P = .0001).
Fifteen (9%) DC and 12 (8%) D patients developed febrile neutropenia.
Grade 3/4 nausea/vomiting (P = .0001), diarrhea (P = .007),
neurotoxicity (P = .017), and nephroroxicity (P = .006) were
significantly more common with DC than with D. There were five
treatment-related deaths in the DC group and one in the D (P = .098).
Conclusion DC regimen resulted in a higher response rate but without
improvement in median time to tumor progession or OS compared with D. D
could be a reasonable front-line chemotherapy for patients who cannot
tolerate cisplatin. (C) 2004 by American Society of Clinical Oncology